Bavarian Nordic A/S (OTCMKTS:BVNRY) Lifted to “Hold” at Zacks Investment Research

Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

Separately, Cowen downgraded Bavarian Nordic A/S from an “outperform” rating to a “market perform” rating in a research note on Friday, February 4th.

Shares of Bavarian Nordic A/S stock traded down $1.80 on Tuesday, hitting $8.76. The stock had a trading volume of 206,938 shares, compared to its average volume of 48,350. The stock has a 50 day moving average of $7.79 and a 200 day moving average of $10.83. Bavarian Nordic A/S has a twelve month low of $5.85 and a twelve month high of $19.25.

Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Rating) last released its quarterly earnings data on Friday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The firm had revenue of $83.65 million during the quarter, compared to the consensus estimate of $93.33 million. Equities analysts anticipate that Bavarian Nordic A/S will post -1.07 EPS for the current year.

About Bavarian Nordic A/S (Get Rating)

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

Read More